Supplementary Figure 4: Administration of LP17 to Trem1-/- mice.
From: Peripheral TREM1 responses to brain and intestinal immunogens amplify stroke severity
LP17 reduces mortality post-stroke (n=26 mice per group; Log-rank test * P =0.011). LP17 administered at 4.5h after MCAo does not affect survival (n=28–36 mice per group). Neuroscores of Trem1-/- mice that underwent MCAo and received LP17 or scrambled peptide at the time of reperfusion (n=8 mice per group; mean +/- SEM). Percent infarct volume in Trem1-/- mice treated with LP17 or scrambled peptide (n= 8 mice per group, mean +/- SEM). Representative histogram of TREM2 expression on CD11b+CD45+Ly6G+ PMNs 2 days after MCAo +/- LP17 or scrambled peptide treatment at time of reperfusion. Body weights of sham and MCAo mice from Fig. 4m-n. Number of left front and left hind paw slips in beam-tested mice (n=5 sham, n=8 scrambled, n=11 LP17).
